Travere Therapeutics

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Travere Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 3 currently recruiting 4 completed top decile by trial count

Travere Therapeutics: 12 sponsored US clinical trials, 3 recruiting.

Travere Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 5 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Focal Segmental Glomerulosclerosis, with 4 trials.

Top-decile sponsor footprint

Travere Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 4

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

NCT07219121
RECRUITING Phase 2

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986
RECRUITING

Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)

NCT02998710
ACTIVE NOT RECRUITING Phase 3

A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment

NCT06247085
ACTIVE NOT RECRUITING Phase 1

Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)

NCT03406611
ACTIVE NOT RECRUITING Phase 3

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850
ACTIVE NOT RECRUITING Phase 3

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT03493685
COMPLETED Phase 2

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

NCT05856760
COMPLETED

Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)

NCT05200871
TERMINATED Phase 3

Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants

NCT03041116
COMPLETED

Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

NCT02638220
COMPLETED Phase 2

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

NCT01613118

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 4
Phase 4 1

Therapeutic Areas

Focal Segmental Glomerulosclerosis 4
Immunoglobulin A Nephropathy 4
Homocystinuria 2
Homocystinuria Due to CBS Deficiency 1
Immunoglobulin A (IgA) Nephropathy 1
Proteinuria 1
Alport Syndrome 1
IgA Vasculitis 1
Minimal Change Disease 1
Kidney Transplant 1

What is open in the Travere Therapeutics pipeline

3 recruiting of 12 indexed (25% open); 4 completed (33%).

Phase mix: 5 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Focal Segmental Glomerulosclerosis (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Travere Therapeutics: open-pipeline peers nationwide

Peers matched on 12 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

Travere Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 2468101214 0%10%20%30% Total trials Recruiting share Travere TherapeuticsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAB ScienceAbbott Point of CareAbdul Latif Jameel Poverty Action LabAccutar Biotechnology
Travere Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Travere Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Travere Therapeutics page

12 registered trials is a research-attention snapshot, not an endorsement of Travere Therapeutics or any single study.

  • 3 of Travere Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Focal Segmental Glomerulosclerosis is the condition Travere Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Focal Segmental Glomerulosclerosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Travere Therapeutics pipeline card: 12 registered trials from official public datasets.Report a data error.